THE ROLE OF LIRAGLUTIDE TREATMENT ON WEIGHT LOSS FOR PATIENTS WITH SUBOPTIMAL INITIAL RESPONSE OR WEIGHT REGAIN AFTER BARIATRIC SURGERY

Mohammed, Ahmed; Merdan, Issam; Algazgooz, Falih

doi:10.33762/basjsurg.2025.163362.1137

	THE ROLE OF LIRAGLUTIDE TREATMENT ON WEIGHT LOSS FOR PATIENTS WITH SUBOPTIMAL INITIAL RESPONSE OR WEIGHT REGAIN AFTER BARIATRIC SURGERY
Basrah Journal of Surgery
Article 3, Volume 31, Issue 2, 2025, Pages 20-32 PDF (1.22 M)
Document Type: Original Article
DOI: 10.33762/basjsurg.2025.163362.1137
Authors
Ahmed Mohammed¹; Issam Merdan^* ²; Falih Algazgooz³
¹Al-Sader Teaching Hospital,Basrah,Iraq
²Department of Surgery. College of medicine, University of Basrah. Basrah. Iraq
³Al-Sader Teaching Hospital,Basrah,Iraq,
Abstract
ABSTRACT: Background: Glucagon-like peptide-1 receptor agonists (GLP1-RAs) are a form of incretin-based therapy that treats hyperglycemia and, in some situations, cardiovascular risk in persons with type 2 diabetes. Aim: Is to determine the efficacy and safety of prescribing GLP1-RAs for patients who had suboptimal initial response or regained weight after bariatric surgery. PatientsandMethodes: A retrospective cross-sectional study was done from the 1st of February /2023 to the 1st of August/2024 in Al-Sadr Teaching Hospital, Iraq. Clinical data including (age, sex, height, weight, BMI, any chronic disease, time of bariatric surgery) were collected. Eighty-six patients were divided into two groups for the study. Seventy-two patients in the first group who gained weight after the weight nadir at least a year after bariatric surgery, 14 patients in the second group who had suboptimal initial response 12 months following bariatric surgery. Liraglutide was administered for 4 -8 months for both groups. Results: The study revealed that 70.9% of patients from both groups responded to the GLP1 therapy, with slightly higher responsiveness in the weight regain group (73.61%) than in the Suboptimal initial response group (57.14%), the difference was not statistically significant (p = 0.358). Both groups significantly reduced their BMI, with a mean pre-treatment to post-treatment BMI difference of 6.02 ±1.97 in the Suboptimal initial response group and 6.06 ± 1.21 in the weight regain group. However, there was no statistically significant difference between the two groups (p = 0.18). Both groups lost weight, with the Suboptimal initial response group losing 10.9% of their weight from pretreatment to post-treatment and the weight regain group gaining 11.3%. There was no statistically significant difference between the two groups (p = 0.112). Conclusion: We discovered that liraglutide 3.0 mg helped post-bariatric surgery patients who had either too much weight gain or insufficient weight loss.
Keywords
bariatric surgery; wight loss; GLP1

Statistics Article View: 313 PDF Download: 166